Evidence map›Paper›PMID 42871601›Full record

ArticleInternational journal of pharmaceutics: X2026

Redox-metabolic cascade NIR-II prodrug for synchronizing compensatory HSPs/P-gp feedback with mitophagy flux impairment against intrinsic thermotolerance.

Lan Cui, Weishuang Lou, Wencan Zhou, Mengyao Sun, Zhongchen Jiao, Mengdi Li, Tong Wang, Xinyu Liang, Xinmeng Jing, Shuoye Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lan CuiSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Weishuang LouSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Wencan ZhouSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Mengyao SunSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Zhongchen JiaoSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Mengdi LiSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Tong WangSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Xinyu LiangSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Xinmeng JingSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Shuoye YangSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Pengshuai ZhangSchool of Biological Engineering, Henan University of Technology, Zhengzhou 450001, PR China.
Lingbo QuInstitute of Chemistry, Henan Academy of Sciences, Zhengzhou 450046, PR China.
Peng LiInstitute for Complexity Science, Henan University of Technology, Zhengzhou 450001, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intrinsic proteostasis of HSPs/P-gp remains formidable barriers in the multidrug resistance (MDR) and thermotolerance. To dismantle the compensatory HSPs and P-gp defense axis, we developed a metabolic reprogramming NIR-II nanoprodrug Lipid 2-DG@Au/DOX-ss, using gold liposome-nanorod loaded disulfide-doxorubicin prodrug DOX-ss and 2-deoxy-d-glucose (2-DG). Results revealed 2-DG dose-dependent metabolic perturbations of ATP, glucose, NAD

Indexed as

HSPsMetabolic homeostasisMitophagy fluxNanoprodrugNIR-IIThermotolerance

Identifiers

PMID42871601
PMCPMC13659683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.